A 2022 review of semaglutide as a treatment for overweight and obesity recorded an average reduction in body weight of 14.44% in STEP clinical trial participants after 68 weeks of 2.4mg weekly injections
41St Street, Suite #412, Miami Beach, FL 33140
This is the most popular option and works well with the peptide calculator for verification
10.1210/endocr/bqad153 50 MaoT.ZhangC.YangS.BiY.LiM.YuJ
The SELECT trial, completed in 2023 with over 17,600 participants, showed a 20% reduction in cardiovascular events in patients with established cardiovascular disease and overweight or obesity without diabetes
When administered as a once-weekly injection, semaglutide helps you feel fuller for longer periods and reduces cravings, leading to consuming fewer calories